BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OMS103HP: Phase III data

Data from a pair of double-blind, North American Phase III trials in a total of 560 patients undergoing arthroscopic ACL reconstruction surgery showed that OMS103HP missed undisclosed pre-specified endpoints vs. placebo. Omeros said that no conclusions could be made...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >